Ergomed
↗Guildford, United Kingdom
Ergomed is a global Contract Research Organization (CRO) and pharmacovigilance (PV) services provider specializing in complex clinical trials, particularly in oncology and rare diseases. The company offers a full range of services from early-stage development through post-approval, including medical information and regulatory compliance.
Following its acquisition by the private equity firm Permira in 2023, Ergomed operates as a private entity. The company is known for its medic-to-medic engagement model and its ability to manage complex, patient-centric clinical programs globally across North America, Europe, and Asia.
CLASSIFICATION
Company Type:CRO
Therapeutic Areas:
Industry:CRO
Sub-Industry:Oncology and Rare Disease specialized CRO
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$150M-$250M
Founded:1997
Ownership:subsidiary
Status:acquired
FUNDING
Investors:Permira
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Service provider)
Modalities:Small molecule, Biologics, Orphan drugs
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Permira
Acquired By:Permira (2023-09-01)
Subsidiaries:PrimeVigilance, ADAMAS Consulting, MedSource, PSR Group
Key Partnerships:Allergy Therapeutics (Co-development partnership)
COMPETITION
Position:Leader
Competitors:TFS, Parexel, Syneos Health, ProPharma Group
LEADERSHIP
Key Executives:
Miroslav Reljanović - Executive Chairman
Scientific Founders:Miroslav Reljanović
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Ergomed and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ergomed. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.